Celebrating the 10th Anniversary of the International mRNA Health Conference

At Moderna, we believe deeply in the value of collaboration, not only with fellow leaders in mRNA science, but also with pharmaceutical and biotech partners, suppliers, and academics. True innovation doesn’t happen in a vacuum, which is why we have been involved in the International  mRNA Health Conference since its inception. 

2022 marks the 10th anniversary of the mRNA Health Conference, jointly organized by Moderna, BioNTech and CureVac, the only annual conference dedicated solely to mRNA-based science and medicine. The event brings together thought leaders from pharma, biotech and academic institutions to learn the latest on the rapidly expanding science, business, and regulatory landscape of mRNA medicine.  

Beginning with the first annual meeting in 2013, the early years of the conference focused on laying the foundation for a new sector of medicines using mRNA. As the promise of mRNA technology continued to accelerate due to the publication of significant peer-reviewed clinical studies and investments in mRNA, attendance grew to over 300. In recent years, rapid clinical progress and cross-industry collaboration have led to innovations in mRNA delivery and design with attendance growing to more than 850. 

This year, reflective of the rapid advancement of mRNA medicines, Moderna’s Chief Scientific Officer, Emeritus, Melissa Moore opened the conference with a series of presentations on the state-of-the-art of mRNA medicines. Deeper dives followed: Charbel Haber, SVP, Global Regulatory Science at Moderna chaired a regulatory roundtable focused on lessons learned from the COVID-19 pandemic, and Scott Nickerson, SVP, US Manufacturing at Moderna led a session around Chemistry, Manufacturing, and Controls (CMC) and quality control. 

The evolution of the International mRNA Health Conference tells the story of a new class of medicines coming into its own. In many ways, the conference’s evolution mirrors Moderna’s growth as a company. Since our founding in 2010, we have built a diverse clinical portfolio of mRNA vaccines and therapeutics across seven modalities. We have pioneered the development of our mRNA platform and have expanded our pipeline to 48 development programs, including 35 in clinical studies. We continue to invest in optimizing mRNA medicines and exploring new applications to meet unmet medical needs and global health threats. And to prepare for the future of mRNA, Moderna is dedicated to building a first-class and diverse workforce skilled in the science and manufacturing of mRNA. 

The breadth of topics discussed during the conference reflects the potential for mRNA as medicine. The success of COVID-19 mRNA vaccines has accelerated investments to advance the science and provided the momentum needed to realize the potential of mRNA for improving health. We have reached a turning point for mRNA science, and we are confident that through our collective efforts the field is poised to transform medicine.